<DOC>
	<DOCNO>NCT01047540</DOCNO>
	<brief_summary>The aim study find whether AIC316 safe efficacious prevention reactivation genital herpes</brief_summary>
	<brief_title>Safety Efficacy Study New Antiviral Drug Treat Genital Herpes Type 2</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Adult , Immunocompetent men woman good health ethnic group History recurrent episode genital herpes least 12 month Seropositive Herpes Simplex Virus HSV Type 2 Body Mass Index ( BMI ) 18 35 kg/m2 Present episode genital herpes Intake systemic drug HSV topical application HSV within 7 day randomization trial Intake systemic corticosteroid , immunomodulating agent investigational agent within 3 month randomization trial Positive result virology test human immunodeficiency virus antibody ( HIVAb ) , hepatitis C antibody ( HCVAb ) , hepatitis B surface antigen ( HBsAg ) hepatitis B core antibody ( HBcAb )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>